<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - KETOCONAZOLE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>KETOCONAZOLE</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#drugAction" data-toggle="tab">Drug action</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#nationalFunding" data-toggle="tab">National funding/access decisions</a></li>
          <li><a href="#importantSafetyInformation" data-toggle="tab">Important safety information</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#conceptionAndContraception" data-toggle="tab">conception and contraception</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#exceptionsToLegalCategory" data-toggle="tab">Exceptions to legal category</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Endogenous Cushing's syndrome (specialist use only)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 400&#8211;600 mg daily in 2&#8211;3 divided doses, increased to 800&#8211;1200 mg daily; maintenance 400&#8211;800 mg daily in 2&#8211;3 divided doses, for dose titrations in patients with established dose, adjustments in adrenal insufficiency, or concomitant corticosteroid replacement therapy, consult product literature; maximum 1200 mg per day.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Tinea pedis</span>,
            </h4>
            <p class="specificity"><span class="route">To the skin using cream</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Apply twice daily.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Fungal skin infection (not Tinea pedis)</span>,
            </h4>
            <p class="specificity"><span class="route">To the skin using cream</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Apply 1&#8211;2 times a day.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Treatment of seborrhoeic dermatitis and dandruff</span>,
            </h4>
            <p class="specificity"><span class="route">To the skin</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Apply twice weekly for 2&#8211;4 weeks, leave preparation on for 3&#8211;5 minutes before rinsing.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                Apply twice weekly for 2&#8211;4 weeks, leave preparation on for 3&#8211;5 minutes before rinsing.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prophylaxis of seborrhoeic dermatitis and dandruff</span>,
            </h4>
            <p class="specificity"><span class="route">To the skin</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Apply every 1&#8211;2 weeks, leave preparation on for 3&#8211;5 minutes before rinsing.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                Apply every 1&#8211;2 weeks, leave preparation on for 3&#8211;5 minutes before rinsing.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Treatment of pityriasis versicolor</span>,
            </h4>
            <p class="specificity"><span class="route">To the skin</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Apply once daily for maximum 5 days, leave preparation on for 3&#8211;5 minutes before rinsing.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                Apply once daily for maximum 5 days, leave preparation on for 3&#8211;5 minutes before rinsing.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prophylaxis of pityriasis versicolor</span>,
            </h4>
            <p class="specificity"><span class="route">To the skin</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Apply once daily for up to 3 days before sun exposure, leave preparation on for 3&#8211;5 minutes before rinsing.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                Apply once daily for up to 3 days before sun exposure, leave preparation on for 3&#8211;5 minutes before rinsing.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Vaginal and vulva candidiasis</span>,
            </h4>
            <p class="specificity"><span class="route">By vagina using cream</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Apply 1&#8211;2 times a day, to be applied to the anogenital area.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>


      <section class="tab-pane" id="drugAction">
        <h2>Drug action</h2>

            <section class="drugAction">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use</h3>
              <p>An imidazole derivative which acts as a potent inhibitor of cortisol and aldosterone synthesis by inhibiting the activity of 17&#945;-hydroxylase, 11-hydroxylation steps and at higher doses the cholesterol side-chain cleavage enzyme.</p><p>It also inhibits the activity of adrenal C17-20 lyase enzymes resulting in androgen synthesis inhibition, and may have a direct effect on corticotropic tumour cells in patients with Cushing's disease.</p>
            </section>
      </section>

      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use</h3>
              <p>Manufacturer advises avoid&#8212;teratogenic in <i>animal</i> studies.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use</h3>
              <p>Avoid in acute or chronic impairment.</p><p>Do not initiate treatment if liver enzymes greater than 2 times the normal upper limit.</p>
            </section>
      </section>


      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

        
          <h3>Specific side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> abdominal pain, adrenal insufficiency, diarrhoea, hepatic enzymes increased, nausea, pruritus, rash, vomiting,
              </p>
              <p>
                <strong>uncommon:</strong> alopecia, dizziness, headache, malaise, somnolence, thrombocytopenia, urticaria,
              </p>
              <p>
                <strong>rare:</strong> hepatic failure, hepatitis, jaundice, liver damage,
              </p>
              <p>
                <strong>veryRare:</strong> pyrexia,
              </p>
              <p>
                <strong>notKnown:</strong> alcohol intolerance, anorexia, arthralgia, azoospermia, dermatitis, dry mouth, dysgeusia, dyspepsia, epistaxis, erectile dysfunction, erythema, flatulence, gynaecomastia, hot flush, increased appetite, insomnia, menstrual disorder, myalgia, nervousness, paraesthesia, peripheral oedema, photophobia, photosensitivity, raised intracranial pressure, reduced testosterone concentrations, tongue discoloration, xeroderma, erythema, hypersensitivity reactions, itching, mild burning sensation, occasional local irritation,
              </p>
        
            <section class="advice">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use</h3>
                <p class="title">Hepatotoxicity</p>
              <p>Potentially life-threatening hepatotoxicity reported rarely.</p>
            </section>
            <section class="advice">
              <h3 class="specificity">With <ph outputclass="route">topical</ph> use</h3>
              <p>Treatment should be discontinued if side-effects are severe.</p>
            </section>
        
      </section>


      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use</h3>
              <p>Patients or their carers should be told how to recognise signs of liver disorder, and advised to discontinue treatment and seek prompt medical attention if symptoms such as anorexia, nausea, vomiting, fatigue, jaundice, abdominal pain, or dark urine develop.</p><p>Patients or their carers should also be told how to recognise signs of adrenal insufficiency.</p>
            </section>
      </section>

      <section class="tab-pane" id="nationalFunding">
        <h2>National funding/access decisions</h2>

      </section>

      <section class="tab-pane" id="importantSafetyInformation">
        <h2>Important safety information</h2>

            <section class="importantSafetyInformation">
                <h3>CHMP advice: Ketoconazole (July 2013)</h3>
              <p> The CHMP has recommended that the marketing authorisation for oral ketoconazole to treat fungal infections should be suspended. The CHMP concluded that the risk of hepatotoxicity associated with oral ketoconazole is greater than the benefit in treating fungal infections. Doctors should review patients who are being treated with oral ketoconazole for fungal infections, with a view to stopping treatment or choosing an alternative treatment. Patients with a prescription of oral ketoconazole for fungal infections should be referred back to their doctors.</p><p>Oral ketoconazole for Cushing's syndrome and topical products containing ketoconazole are not affected by this advice.</p>
            </section>
      </section>

      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
              <strong>With oral use:</strong>
            risk of adrenal insufficiency
          </li>
          <li>
              <strong>With topical use:</strong>
            avoid contact with eyes
          </li>
          <li>
              <strong>With topical use:</strong>
            avoid contact with mucous membranes
          </li>
        </ul>
      </section>

      <section class="tab-pane" id="conceptionAndContraception">
        <h2>Advice regarding conception and contraception</h2>

            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use</h3>
              <p>Effective contraception must be used in women of child-bearing potential.</p>
            </section>
            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">topical</ph> use in adults</h3>
              <p>Effect on latex condoms and diaphragms not yet known.</p>
            </section>
      </section>

      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use</h3>
              <p>Monitor ECG before and one week after initiation, and then as clinically indicated thereafter.</p>
            </section>
            <section class="patientParameters">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use</h3>
                <p class="title">Adrenal insufficiency</p>
              <p>Monitor adrenal function within one week of initiation, then regularly thereafter. When cortisol levels are normalised or close to target and effective dose established, monitor every 3&#8211;6 months as there is a risk of autoimmune disease development or exacerbation after normalisation of cortisol levels. If symptoms suggestive of adrenal insufficiency such as fatigue, anorexia, nausea, vomiting, hypotension, hyponatraemia, hyperkalaemia, and/or hypoglycaemia occur, measure cortisol levels and discontinue treatment temporarily (can be resumed thereafter at lower dose) or reduce dose and if necessary, initiate corticosteroid substitution.</p>
            </section>
            <section class="patientParameters">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use</h3>
                <p class="title">Hepatotoxicity</p>
              <p>Monitor liver function before initiation of treatment, then weekly for 1 month after initiation, then monthly for 6 months&#8212;more frequently if dose adjusted or abnormal liver function detected. Reduce dose if liver enzymes increase less than 3 times the normal upper limit&#8212;consult product literature; if liver enzymes are raised to 3 times or greater the normal upper limit, discontinue treatment permanently.</p>
            </section>
      </section>









      <section class="tab-pane" id="exceptionsToLegalCategory">
        <h2>Exceptions to legal category</h2>

            <section class="exceptionsToLegalCategory">
              <h3 class="specificity">With <ph outputclass="route">topical</ph> use for <ph outputclass="indication">Fungal skin infections</ph> in adults</h3>
              <p>A 15-g tube is available for sale to the public for the treatment of tinea pedis, tinea cruris, and candidal intertrigo.</p>
            </section>
            <section class="exceptionsToLegalCategory">
              <h3 class="specificity">With <ph outputclass="route">topical</ph> use for <ph outputclass="indication">Seborrhoeic dermatitis and dandruff</ph></h3>
              <p>Can be sold to the public for the prevention and treatment of dandruff and seborrhoeic dermatitis of the scalp as a shampoo formulation containing ketoconazole maximum 2%, in a pack containing maximum 120&#8239;mL and labelled to show a maximum frequency of application of once every 3 days.</p>
            </section>
      </section>


      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of KETOCONAZOLE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            oral suspension,

            <div id="PHP107979"><a href="../medicinalForm/PHP107979.html" data-target="#PHP107979" data-action="load">Tablet</a></div>
            <div id="PHP75801"><a href="../medicinalForm/PHP75801.html" data-target="#PHP75801" data-action="load">Cream</a></div>
            <div id="PHP75819"><a href="../medicinalForm/PHP75819.html" data-target="#PHP75819" data-action="load">Shampoo</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
